PEMETREXED AND CARBOPLATIN VERSUS DOCETAXEL AND CARBOPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Ganju, Vinod [1 ]
Pereira, Jose [2 ]
Kim, Joo-Hang [3 ]
Magallanes, Manuel [4 ]
Lee, Dae-Ho [5 ]
Wang, Jie [6 ]
Martinez, Luis [7 ]
Barraclough, Helen
Van Kooten, Maximiliano
Orlando, Mauro
机构：
[1] Frankston Private Hosp, Peninsula Oncol Ctr, Frankston, Vic, Australia
[2] Inst Arnaldo Vieira De Carvalho, Oncopneumol Dept, Sao Paulo, Brazil
[3] Yonsei Canc Ctr, Seoul, South Korea
[4] Mil Hosp Mexico, Dept Med Oncol, Mexico City, DF, Mexico
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Ulsan, South Korea
[6] Beijing Canc Hosp & Inst, Dept Thorac Oncol, Beijing, Peoples R China
[7] Natl Inst Resp Dis, Dept Oncol, Mexico City, DF, Mexico
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
Pemetrexed; Docetaxel; Non-squamous nsmall cell lung cancer; Carboplatin;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S417 / S418
页数：2
相关论文
共 50 条
  • [21] RESPONSE RATES TO CARBOPLATIN AND PEMETREXED IN NON-SQUAMOUS NON-SMALL CELL LUNG CANCER - A SINGLE CENTRE AUDIT
    Talbot, Toby L. J.
    Collinson, Matthew P.
    Buscombe, Charlotte
    Pascoe, Susan
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1210 - S1210
  • [22] Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer
    Yuichi Takiguchi
    Shunichiro Iwasawa
    Koichi Minato
    Yosuke Miura
    Akihiko Gemma
    Rintaro Noro
    Kozo Yoshimori
    Masato Shingyoji
    Mitsunori Hino
    Masahiro Ando
    Hiroaki Okamoto
    International Journal of Clinical Oncology, 2015, 20 : 659 - 667
  • [23] Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29)
    Renaud, Emmanuelle
    Ricordel, Charles
    Corre, Romain
    Leveiller, Guillaume
    Gadby, Florence
    Babey, Helene
    Annic, Josselin
    Lucia, Francois
    Bourbonne, Vincent
    Robinet, Gilles
    Descourt, Renaud
    Orione, Charles
    Quere, Gilles
    Geier, Margaux
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (02) : 266 - +
  • [24] First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China
    Chang, Qing
    Zhang, Yanwei
    Xu, Jianlin
    Zhong, Runbo
    Qiang, Huiping
    Zhang, Bo
    Han, Baohui
    Qian, Jialin
    Chu, Tianqing
    THORACIC CANCER, 2019, 10 (05) : 1043 - 1050
  • [25] Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin
    Tiseo, Marcello
    Giovannetti, Elisa
    Tibaldi, Carmelo
    Camerini, Andrea
    Di Costanzo, Francesco
    Barbieri, Fausto
    Burgers, Jacobus A.
    Vincent, Andrew
    Peters, Godefridus J.
    Smith, Egbert F.
    Ardizzoni, Andrea
    LUNG CANCER, 2012, 78 (01) : 92 - 99
  • [26] A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer
    Spigel, David R.
    Hainsworth, John D.
    Shipley, Dianna L.
    Ervin, Thomas J.
    Kohler, Peter C.
    Lubiner, Eric T.
    Peyton, James D.
    Waterhouse, David M.
    Burris, Howard A., III
    Greco, F. Anthony
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (01) : 196 - 202
  • [27] Combination Chemotherapy with Docetaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer
    W. Schuette
    I. Bork
    B. Wollschläger
    S. Schädlich
    Clinical Drug Investigation, 2001, 21 : 161 - 168
  • [28] Pemetrexed in first-line treatment of non-small cell lung cancer
    Esteban, Emilio
    Casillas, Marta
    Cassinello, Alejo
    CANCER TREATMENT REVIEWS, 2009, 35 (04) : 364 - 373
  • [29] Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer
    Zhao, Xinmin
    Yu, Hui
    Zhao, Jing
    Wu, Xianghua
    Sun, Si
    Luo, Zhiguo
    Wang, Huijie
    Qiao, Jie
    Chang, Jianhua
    Wang, Jialei
    ONCOTARGET, 2017, 8 (49) : 86384 - 86394
  • [30] Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer: treating the right patients based on individualized treatment effect prediction
    van Kruijsdijk, R. C. M.
    Visseren, F. L. J.
    Boni, L.
    Groen, H. J. M.
    Dingemans, A. M. C.
    Aerts, J. G. J. V.
    van der Graaf, Y.
    Ardizzoni, A.
    Smit, E. F.
    ANNALS OF ONCOLOGY, 2016, 27 (07) : 1280 - 1286
12345